Cascadia Advisory Services LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 14.3% during the second quarter, HoldingsChannel reports. The firm owned 16,231 shares of the company’s stock after buying an additional 2,025 shares during the quarter. Cascadia Advisory Services LLC’s holdings in Johnson & Johnson were worth $2,674,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently bought and sold shares of JNJ. OLD Mission Capital LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth approximately $362,000. Lehman & Derafelo Financial Resources LLC boosted its position in Johnson & Johnson by 3.8% during the 1st quarter. Lehman & Derafelo Financial Resources LLC now owns 15,728 shares of the company’s stock worth $2,585,000 after buying an additional 578 shares during the period. Ironwood Wealth Management LLC. boosted its position in Johnson & Johnson by 37.3% during the 1st quarter. Ironwood Wealth Management LLC. now owns 10,161 shares of the company’s stock worth $1,670,000 after buying an additional 2,761 shares during the period. Abundance Wealth Counselors boosted its position in Johnson & Johnson by 9.5% during the 1st quarter. Abundance Wealth Counselors now owns 8,879 shares of the company’s stock worth $1,459,000 after buying an additional 771 shares during the period. Finally, Grace Capital boosted its position in Johnson & Johnson by 2.7% during the 1st quarter. Grace Capital now owns 7,489 shares of the company’s stock worth $1,231,000 after buying an additional 200 shares during the period. Institutional investors own 67.29% of the company’s stock.
NYSE JNJ traded up $1.22 during mid-day trading on Tuesday, hitting $165.03. The company’s stock had a trading volume of 78,828 shares, compared to its average volume of 7,128,558. The company’s 50 day simple moving average is $172.08 and its 200 day simple moving average is $167.41. Johnson & Johnson has a twelve month low of $133.65 and a twelve month high of $179.92. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $434.44 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 2.23 and a beta of 0.71.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Shareholders of record on Tuesday, August 24th were issued a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date was Monday, August 23rd. Johnson & Johnson’s dividend payout ratio is 52.80%.
Several research analysts have issued reports on the stock. Credit Suisse Group set a $193.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. Morgan Stanley lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price target for the company. in a report on Tuesday, September 7th. Finally, SVB Leerink restated a “buy” rating on shares of Johnson & Johnson in a report on Thursday, July 29th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $190.38.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Read More: Yield Curve
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.